Literature DB >> 8061375

Acute rejection episodes--best predictor of long-term primary cadaveric renal transplant survival.

R Ferguson1.   

Abstract

Uniformly high 1-year primary cadaveric renal transplant survival has prompted an interest in establishing clinical factors associated with longer-term (i.e., more than 5-year) graft survival. We have studied 665 consecutive primary transplanted cadaveric kidneys using sequential quadruple immunosuppression with at least 1 year of follow-up (average 41.4 months). No attempt at HLA matching was made and all rejection episodes were confirmed by histology. Overall, 8-year patient and graft survival were 78% and 60%, respectively. Death as a cause of graft loss occurred in 103 patients. However, only 14 patients died from complications of immunosuppression. A multivariate analysis was performed using age, sex, blood type, race, presence of diabetes, HLA mismatch, current and maximum panel reactive antibody (PRA), time to first rejection episode, treatment of first rejection episode, and number of rejection episodes (none, one, or more than one). Number of rejection episodes was by far the most important co-variate (p = < 0.00001). In total, 53% of patients had no rejection episodes, 25% had one, and 22% had more than one. The occurrence of acute rejection did not correlate with the degree of HLA mismatch or PRA. Demographic and immunologic variables were similar for all three groups. Actuarial 8-year graft survival was negatively affected by rejection history (Fig. 1). Uncensored T1/2 in the group with no rejection episodes was 16.9 years, compared with 3.9 years in the group that experienced more than one such episode.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8061375

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  13 in total

1.  Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells.

Authors:  Birgit Fogal; Tai Yi; Chen Wang; Deepak A Rao; Amir Lebastchi; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  J Immunol       Date:  2011-11-14       Impact factor: 5.422

2.  Does mycophenolate mofetil decrease the recurrent acute rejection in renal transplant recipients.

Authors:  Aneesh Srivastava; Vishwajeet Singh; Devendra Kumar; Anant Kumar; R K Sharma
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

Review 3.  The role of complement in antibody-mediated rejection in kidney transplantation.

Authors:  Mark D Stegall; Marcio F Chedid; Lynn D Cornell
Journal:  Nat Rev Nephrol       Date:  2012-10-02       Impact factor: 28.314

Review 4.  Hyperfiltration nephropathy as a cause of late graft loss in renal transplantation.

Authors:  C Modlin; D Goldfarb; A C Novick
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

5.  Higher infiltration by Th17 cells compared with regulatory T cells is associated with severe acute T-cell-mediated graft rejection.

Authors:  Byung Ha Chung; Hye Jwa Oh; Shang Guo Piao; In O Sun; Seok Hui Kang; Sun Ryoung Choi; Hoon Suk Park; Bum Soon Choi; Yeong Jin Choi; Cheol Whee Park; Yong Soo Kim; Mi La Cho; Chul Woo Yang
Journal:  Exp Mol Med       Date:  2011-11-30       Impact factor: 8.718

Review 6.  Basiliximab.

Authors:  S V Onrust; L R Wiseman
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

Review 7.  Through a glass darkly: seeking clarity in preventing late kidney transplant failure.

Authors:  Mark D Stegall; Robert S Gaston; Fernando G Cosio; Arthur Matas
Journal:  J Am Soc Nephrol       Date:  2014-08-05       Impact factor: 10.121

8.  Cost evaluation of basiliximab treatment for renal transplant patients in Japan.

Authors:  Tomonori Hasegawa; Hidehiko Imai; Sunao Miki
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  Lymphotactin: a key regulator of lymphocyte trafficking during acute graft rejection.

Authors:  J D Wang; N Nonomura; S Takahara; B S Li; H Azuma; N Ichimaru; Y Kokado; K Matsumiya; T Miki; S Suzuki; A Okuyama
Journal:  Immunology       Date:  1998-09       Impact factor: 7.397

10.  Basiliximab induction therapy in kidney transplantation: benefits for long term allograft function after 10 years?

Authors:  Martina Koch; Thomas Becker; Rainer Lueck; Michael Neipp; Juergen Klempnauer; Bjoern Nashan
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.